Corcept soars as ovarian cancer drug succeeds late-stage trial

Shares of drugmaker Corcept Therapeutics CORT.O soar 91% to $104.69 premarket

CORT says its experimental drug for ovarian cancer in combination with chemotherapy met the main goal of a late-stage trial

Co says the drug, relacorilant, when combined with chemotherapy agent nab-paclitaxel, showed a 30% reduction in disease-progression risk in platinum-resistant ovarian cancer patients, compared to those treated with chemotherapy alone

Platinum-resistant ovarian cancer is a type of ovarian cancer that doesn't responds to platinum-based chemotherapy treatments, which are typically used as a first-line therapy

As of last close, CORT shares rise up 8.4% YTD